
Arog is a late-stage, privately held U.S. biopharmaceutical company enrolling pivotal studies for crenolanib, an oral TKI with best-in-class profile for FLT3-mutated AML. Preliminary clinical data in solid tumors (gastric cancer, glioma, sarcoma, and lung cancer) have also been generated.
Address
DallasTX
United States